<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003263</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066157</org_study_id>
    <secondary_id>P30CA006927</secondary_id>
    <secondary_id>FCCC-96087</secondary_id>
    <secondary_id>NCI-G98-1401</secondary_id>
    <nct_id>NCT00003263</nct_id>
  </id_info>
  <brief_title>Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma</brief_title>
  <official_title>Phase I Combined Modality Protocol for Malignant Mesothelioma: Cisplatin &amp; rIFN-alpha-2b Followed by Surgical Resection (Debulking), and Post-Op Concurrent Chemoradiotherapy With Cisplatin, +/- rIFN-alpha-2b</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy,&#xD;
      radiation therapy, and interferon alfa may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of cisplatin plus interferon alfa followed&#xD;
      by surgery and interferon alfa plus radiation therapy in treating patients with malignant&#xD;
      pleural mesothelioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of neoadjuvant interferon alfa 2b&#xD;
      (IFN-A2b) administered with cisplatin in patients with malignant pleural mesothelioma. II.&#xD;
      Determine the MTD of IFN-A2b administered with radiation therapy and cisplatin after surgery&#xD;
      in these patients. III. Determine the response rate and toxicity of induction therapy with&#xD;
      IFN-A2b and cisplatin in these patients. IV. Determine the toxicity of concurrent radiation&#xD;
      therapy, cisplatin, and IFN-A2b after surgery in these patients. V. Determine the local&#xD;
      control rate, freedom from progression, median survival, and long term survival of these&#xD;
      patients after combined modality therapy.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study. Patients receive induction therapy consisting of&#xD;
      cisplatin IV weekly and interferon alfa 2b (IFN-A2b) subcutaneously three times a week for 6&#xD;
      weeks. Patients who experience at least 25% tumor shrinkage receive another 4 weeks of&#xD;
      therapy. Patients then undergo debulking surgery to remove all gross tumor, if possible. If&#xD;
      this resection is performed, then patients begin radiation therapy 2-6 weeks after surgery.&#xD;
      Patients with unresectable tumors begin radiation therapy 2-4 weeks after the last course of&#xD;
      induction chemotherapy. Patients undergo radiation therapy 5 days a week for 6 weeks.&#xD;
      Concurrently, patients receive cisplatin IV weekly and IFN-A2b subcutaneously three times a&#xD;
      week. Cohorts of 4 patients each receive escalated doses of IFN-A2b during induction&#xD;
      chemotherapy. Once the maximum tolerated dose (MTD) of IFN-A2b is established, one dose level&#xD;
      below this dose is used for the beginning doses of IFN-A2b during adjuvant chemotherapy. If&#xD;
      no unacceptable toxic effects occur, then the dose of IFN-A2b is escalated to the induction&#xD;
      MTD. Patients are followed at 3-6 weeks after completing radiochemotherapy, then every 3&#xD;
      months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 2-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1996</start_date>
  <completion_date type="Actual">November 2000</completion_date>
  <primary_completion_date type="Actual">December 1999</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">6</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
    <description>vaccine</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven ipsilateral malignant pleural mesothelioma&#xD;
&#xD;
          -  No contralateral thoracic or intra-abdominal involvement&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age: 18 and over&#xD;
&#xD;
          -  Performance status: ECOG 0 or 1&#xD;
&#xD;
          -  Life expectancy: Not specified&#xD;
&#xD;
          -  Hematopoietic:&#xD;
&#xD;
               -  Absolute neutrophil count greater than 2,000/mm3&#xD;
&#xD;
               -  Platelet count greater than 100,000/mm3&#xD;
&#xD;
               -  No symptomatic anemia requiring transfusion&#xD;
&#xD;
          -  Hepatic:&#xD;
&#xD;
               -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
               -  No autoimmune hepatitis&#xD;
&#xD;
               -  No history of decompensated liver disease; e.g. esophageal varices&#xD;
&#xD;
               -  Ascites&#xD;
&#xD;
               -  Albumin at least 2.5 mg/dL&#xD;
&#xD;
               -  Increasing prothrombin time of at least 2.0&#xD;
&#xD;
          -  Renal: Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Cardiovascular:&#xD;
&#xD;
               -  No symptomatic or debilitating cardiovascular disease,&#xD;
&#xD;
               -  No concurrent thrombophlebitic or embolic disorders&#xD;
&#xD;
          -  Pulmonary:&#xD;
&#xD;
               -  No symptomatic or debilitating pulmonary disease,&#xD;
&#xD;
               -  Pretreatment diffusion capacity greater than 30% of predicted normal&#xD;
&#xD;
               -  Projected post-treatment FEV1 at least 1.0 L&#xD;
&#xD;
          -  Other:&#xD;
&#xD;
               -  No prior malignancy within 3 years, except nonmelanomatous skin cancer&#xD;
&#xD;
               -  Carcinoma in situ of the cervix&#xD;
&#xD;
               -  Ductal carcinoma in situ of the breast&#xD;
&#xD;
               -  Not pregnant&#xD;
&#xD;
               -  Fertile patients must use effective contraception&#xD;
&#xD;
               -  No history of hypersensitivity to interferon or any component of the injection&#xD;
&#xD;
               -  No uncontrolled diabetes (blood sugars consistently at least 300 mg/dL)&#xD;
&#xD;
               -  No insulin dependent diabetes mellitus with history of ketoacidosis within 1 year&#xD;
&#xD;
               -  No psychosis&#xD;
&#xD;
               -  No uncontrolled thyroid abnormalities&#xD;
&#xD;
               -  No active infection requiring intravenous antibiotics&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Biologic therapy: No prior biologic therapy&#xD;
&#xD;
          -  Chemotherapy: No prior chemotherapy&#xD;
&#xD;
          -  Endocrine therapy: Not specified&#xD;
&#xD;
          -  Radiotherapy: No prior radiotherapy&#xD;
&#xD;
          -  Surgery:&#xD;
&#xD;
               -  No prior debulking surgery&#xD;
&#xD;
               -  No prior chest tube drainage with sclerosis if tumor resectable&#xD;
&#xD;
               -  Prior thoracentesis allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey J. Langer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Office of S. Terry Kraus</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2004</study_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <name_title>Corey Langer</name_title>
    <organization>FCCC</organization>
  </responsible_party>
  <keyword>localized malignant mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

